Doctor hunts for top-quality stool donors in Boston

Elizabeth Hohmann, an infectious disease specialist at Massachusetts General Hospital, spends her days screening potential stool donors for faecal transplants that treat stubborn gut infections. With only about one percent of respondents qualifying, the process is challenging but rewarding. Her work has restored health to patients who previously couldn't function normally.

For 15 years, Elizabeth Hohmann has led the faecal transplant program at Massachusetts General Hospital in Boston, transforming donated stools into oral capsules to combat recurrent Clostridioides difficile infections. These infections, which cause severe diarrhoea and resist antibiotics, affect many patients, but the transplants introduce beneficial gut bacteria to outcompete the harmful ones.

Finding suitable donors is no easy task. Hohmann advertises online, offering $1,200 for a month's donations, yet only around one percent pass the rigorous checks. Candidates must avoid being healthcare workers or recent travellers to South-East Asia due to risks of drug-resistant bacteria, and they need to be lean to prevent obesity transmission. Successful applicants undergo blood tests for infections like HIV and covid-19, plus a rectal exam for gut issues.

Ideal donors are often fitness buffs with diets heavy on fruits, vegetables, and whole grains, shunning ultra-processed foods. Hohmann notes that while some centres prefer vegans, her top donors have been omnivores. Donations occur over two to four weeks, with donors visiting the hospital daily for bowel movements, often prompted by coffee. The fresh stool is blended with saline, filtered, and encapsulated promptly.

Post-donation re-screening ensures no new infections, like Salmonella, have arisen. The impact is profound: one patient, previously too ill to work, now manages 30 hours weekly. 'I keep doing it because it really does make a huge difference in some people’s lives,' Hohmann says. As retirement nears, she struggles to find a successor, with colleagues recoiling at the hands-on nature of the job.

Relaterede artikler

Illustration of glowing engineered bacterial pills detecting gut bleeding in a mouse intestine model.
Billede genereret af AI

Engineered bacterial ‘pills’ show promise for detecting gut bleeding in mice

Rapporteret af AI Billede genereret af AI Faktatjekket

Researchers have developed tiny ingestible hydrogel microspheres packed with engineered bacteria that glow when they encounter blood in the gut, potentially offering a quick, noninvasive way to monitor intestinal disease. In mouse models of colitis, the sensors detected heme — a component of blood — within minutes and produced stronger signals as disease severity increased.

A small clinical trial shows that faecal microbiota transplants can improve outcomes for kidney cancer patients on immunotherapy drugs. Participants receiving transplants experienced longer cancer stability and greater tumor shrinkage compared to those given placebos. The approach targets the gut microbiome to boost immune responses against tumors.

Rapporteret af AI

A retired US Marine officer in Massachusetts, plagued by a gut that brewed its own alcohol, has seen his symptoms resolve after receiving faecal transplants from a healthy donor. The treatment targeted the rare auto-brewery syndrome, where gut microbes ferment sugars into intoxicating levels of alcohol. This case highlights potential new avenues for managing the condition triggered by antibiotic use.

A British content creator flew to Beijing for faster treatment of persistent stomach pain, highlighting a growing trend of foreigners turning to China's medical system for timely and affordable care. Her story, shared on social media, underscores the efficiency of public hospitals in the country.

Rapporteret af AI

A new study reveals that chemotherapy's damage to the gut lining unexpectedly rewires the microbiota, producing a compound that strengthens immune defenses against cancer spread. This process reduces immunosuppressive cells and enhances resistance to metastasis, particularly in the liver. Patient data links higher levels of this compound to improved survival in colorectal cancer cases.

Researchers led by Helmholtz Munich report that some gut-dwelling bacteria — including strains not typically considered harmful — possess syringe-like molecular machinery that can deliver bacterial proteins into human cells, affecting immune and metabolic signaling. The work also links these bacterial “effector” genes to Crohn’s disease–associated microbiome patterns, though the authors say more studies are needed to determine how the mechanism influences disease.

Rapporteret af AI Faktatjekket

Researchers working at Harvard University and collaborators in Brazil have identified metabolites produced by gut bacteria that travel through the portal vein to the liver and appear to influence energy use and insulin sensitivity in mice. The findings, published in Cell Metabolism, suggest possible new strategies for preventing or treating obesity and type 2 diabetes by targeting gut–liver communication.([sciencedaily.com](https://www.sciencedaily.com/releases/2025/12/251214100926.htm?utm_source=openai))

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis